PE20061390A1 - Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la produccion de las mismas - Google Patents
Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la produccion de las mismasInfo
- Publication number
- PE20061390A1 PE20061390A1 PE2006000515A PE2006000515A PE20061390A1 PE 20061390 A1 PE20061390 A1 PE 20061390A1 PE 2006000515 A PE2006000515 A PE 2006000515A PE 2006000515 A PE2006000515 A PE 2006000515A PE 20061390 A1 PE20061390 A1 PE 20061390A1
- Authority
- PE
- Peru
- Prior art keywords
- same
- hydroxamic acid
- procedures
- production
- suberoylanilide hydroxamic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 title 1
- 229960000237 vorinostat Drugs 0.000 title 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68287505P | 2005-05-20 | 2005-05-20 | |
| US69312805P | 2005-06-23 | 2005-06-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20061390A1 true PE20061390A1 (es) | 2007-01-15 |
Family
ID=37452585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000515A PE20061390A1 (es) | 2005-05-20 | 2006-05-16 | Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la produccion de las mismas |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US8093295B2 (enExample) |
| EP (2) | EP2292221A3 (enExample) |
| JP (2) | JP5264174B2 (enExample) |
| KR (2) | KR100993135B1 (enExample) |
| AR (1) | AR055953A1 (enExample) |
| AU (3) | AU2006249440C1 (enExample) |
| BR (1) | BRPI0605893A (enExample) |
| CA (1) | CA2580367C (enExample) |
| CR (1) | CR8912A (enExample) |
| DO (1) | DOP2006000113A (enExample) |
| EC (1) | ECSP077263A (enExample) |
| IL (1) | IL181070A0 (enExample) |
| MA (1) | MA28804B1 (enExample) |
| MX (1) | MX2007002047A (enExample) |
| MY (1) | MY144613A (enExample) |
| NI (1) | NI200700031A (enExample) |
| NZ (2) | NZ594669A (enExample) |
| PE (1) | PE20061390A1 (enExample) |
| TW (2) | TWI415603B (enExample) |
| WO (2) | WO2006127321A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI415603B (zh) * | 2005-05-20 | 2013-11-21 | Merck Sharp & Dohme | １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法 |
| US8883851B2 (en) | 2008-10-15 | 2014-11-11 | Generics [Uk] Limited | Process for the preparation of vorinostat |
| US20110269838A1 (en) * | 2008-11-26 | 2011-11-03 | Vinayak Gore | Novel processes and pure polymorphs |
| JP2012509929A (ja) * | 2008-11-26 | 2012-04-26 | ジェネリクス・（ユーケー）・リミテッド | 多型 |
| US20110313044A1 (en) * | 2010-06-18 | 2011-12-22 | Urquima S.A. | Polymorphs of Suberoylanilide Hydroxamic Acid |
| WO2018011811A2 (en) * | 2016-07-13 | 2018-01-18 | Rappaport Family Institute For Research In The Medical Sciences | Inhibitors of cytoplasmic histone deacetylase 4 complex for treating or preventing vascular or valve calcification |
| CN107362148B (zh) * | 2017-07-27 | 2020-04-21 | 东曜药业有限公司 | 一种治疗肿瘤的药物组合物及其制备方法和应用 |
| US12186393B2 (en) | 2019-08-02 | 2025-01-07 | Onehealthcompany, Inc. | Method of treating transitional cell carcinoma in a canine by administering lapatinib, wherein the carcinoma harbors a BRAF mutation |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JPS61176523A (ja) | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
| US5055608A (en) | 1988-11-14 | 1991-10-08 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of thermal differentiation and method of use thereof |
| US5608108A (en) | 1988-11-14 | 1997-03-04 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
| US5175191A (en) | 1988-11-14 | 1992-12-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5700811A (en) | 1991-10-04 | 1997-12-23 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| USRE38506E1 (en) | 1991-10-04 | 2004-04-20 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5635532A (en) | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
| JP3170069B2 (ja) * | 1992-10-06 | 2001-05-28 | 日水製薬株式会社 | 徐放性顆粒剤 |
| US6043389A (en) | 1997-03-11 | 2000-03-28 | Mor Research Applications, Ltd. | Hydroxy and ether-containing oxyalkylene esters and uses thereof |
| US6124495A (en) | 1997-03-11 | 2000-09-26 | Beacon Laboratories, Inc. | Unsaturated oxyalkylene esters and uses thereof |
| US6030961A (en) | 1997-03-11 | 2000-02-29 | Bar-Ilan Research & Development Co., Ltd. | Oxyalkylene phosphate compounds and uses thereof |
| US6231880B1 (en) | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
| AUPO721997A0 (en) | 1997-06-06 | 1997-07-03 | Queensland Institute Of Medical Research, The | Anticancer compounds |
| US6262116B1 (en) | 1998-01-23 | 2001-07-17 | Sloan-Kettering Institute For Cancer Research | Transcription therapy for cancers |
| KR20010080142A (ko) | 1998-10-13 | 2001-08-22 | 후지야마 아키라 | 사이클릭 테트라펩티드 화합물 및 이의 용도 |
| WO2000071703A2 (en) | 1999-05-03 | 2000-11-30 | Methylgene Inc. | Inhibition of histone deacetylase |
| JP2001081031A (ja) | 1999-08-30 | 2001-03-27 | Schering Ag | 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤 |
| NZ517613A (en) | 1999-09-08 | 2004-01-30 | Sloan Kettering Inst Cancer | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
| EP1748046A3 (en) | 1999-11-23 | 2007-08-22 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| WO2001070675A2 (en) | 2000-03-24 | 2001-09-27 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| WO2002015921A2 (en) | 2000-08-18 | 2002-02-28 | The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| JP4975941B2 (ja) | 2000-09-29 | 2012-07-11 | トポターゲット ユーケー リミテッド | （ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途 |
| AU2002243231A1 (en) | 2000-11-21 | 2002-07-24 | Wake Forest University | Method of treating autoimmune diseases |
| AR035659A1 (es) | 2000-12-07 | 2004-06-23 | Hoffmann La Roche | Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos |
| US6495719B2 (en) | 2001-03-27 | 2002-12-17 | Circagen Pharmaceutical | Histone deacetylase inhibitors |
| US7314953B2 (en) | 2001-03-27 | 2008-01-01 | Errant Gene Therapeutics, Llc | Treatment of lung cells with histone deacetylase inhibitors |
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| AU2002318364A1 (en) | 2001-06-14 | 2003-01-02 | Bristol-Myers Squibb Company | Novel human histone deacetylases |
| AU2002340253C1 (en) | 2001-10-16 | 2011-03-31 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases and cancer of the brain |
| US20040132643A1 (en) | 2002-01-09 | 2004-07-08 | Fojo Antonio Tito | Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms |
| JP2005525345A (ja) | 2002-02-15 | 2005-08-25 | スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ | Ｔｒｘ媒介性疾患を処置する方法 |
| US20060276547A1 (en) | 2002-03-04 | 2006-12-07 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
| US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
| US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| CN101259120B (zh) | 2002-03-04 | 2012-07-04 | Hdac默克研究有限责任公司 | 辛二酰苯胺异羟肟酸或其可药用盐在制备诱导末期分化的药物的用途 |
| US20070060614A1 (en) | 2002-03-04 | 2007-03-15 | Bacopoulos Nicholas G | Methods of treating cancer with hdac inhibitors |
| AU2003226408B2 (en) | 2002-04-15 | 2007-06-14 | Sloan-Kettering Institute For Cancer Research | Combination therapy for the treatment of cancer |
| DE10218106A1 (de) * | 2002-04-23 | 2003-11-20 | Jenapharm Gmbh | Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen |
| WO2004089293A2 (en) | 2003-04-01 | 2004-10-21 | Memorial Sloan-Kettering Cancer Center | Hydroxamic acid compounds and methods of use thereof |
| SI1663194T1 (sl) * | 2003-08-26 | 2010-08-31 | Merck Hdac Res Llc | Uporaba SAHA za zdravljenje mezotelioma |
| TWI415603B (zh) * | 2005-05-20 | 2013-11-21 | Merck Sharp & Dohme | １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法 |
| US20090227674A1 (en) | 2005-08-18 | 2009-09-10 | Richon Victoria M | Combination methods fo saha and targretin for treating cancer |
| JP2009514879A (ja) | 2005-11-04 | 2009-04-09 | メルク エンド カムパニー インコーポレーテッド | Ｓａｈａ、カルボプラチン及びパクリタキセルを用いて癌を治療する方法及びその他の併用療法 |
| CA2627129A1 (en) | 2005-11-04 | 2007-05-18 | Merck & Co., Inc. | Methods of using saha and bortezomib for treating cancer |
| US20070197568A1 (en) | 2005-11-04 | 2007-08-23 | Paul Bunn | Methods of using SAHA and Erlotinib for treating cancer |
-
2006
- 2006-05-11 TW TW099119337A patent/TWI415603B/zh not_active IP Right Cessation
- 2006-05-11 TW TW095116824A patent/TWI365068B/zh not_active IP Right Cessation
- 2006-05-15 DO DO2006000113A patent/DOP2006000113A/es unknown
- 2006-05-16 KR KR1020087030074A patent/KR100993135B1/ko not_active Expired - Fee Related
- 2006-05-16 NZ NZ594669A patent/NZ594669A/xx not_active IP Right Cessation
- 2006-05-16 AU AU2006249440A patent/AU2006249440C1/en active Active
- 2006-05-16 BR BRPI0605893-0A patent/BRPI0605893A/pt not_active IP Right Cessation
- 2006-05-16 JP JP2007540436A patent/JP5264174B2/ja active Active
- 2006-05-16 WO PCT/US2006/018795 patent/WO2006127321A2/en not_active Ceased
- 2006-05-16 WO PCT/US2006/018737 patent/WO2006127319A2/en not_active Ceased
- 2006-05-16 EP EP10183861A patent/EP2292221A3/en not_active Withdrawn
- 2006-05-16 NZ NZ553204A patent/NZ553204A/en not_active IP Right Cessation
- 2006-05-16 MX MX2007002047A patent/MX2007002047A/es active IP Right Grant
- 2006-05-16 PE PE2006000515A patent/PE20061390A1/es not_active Application Discontinuation
- 2006-05-16 US US11/663,165 patent/US8093295B2/en active Active
- 2006-05-16 EP EP06759843A patent/EP1853245A2/en not_active Ceased
- 2006-05-16 KR KR1020077003998A patent/KR100884500B1/ko not_active Expired - Fee Related
- 2006-05-16 CA CA2580367A patent/CA2580367C/en active Active
- 2006-05-17 MY MYPI20062258A patent/MY144613A/en unknown
- 2006-05-17 AR ARP060101986A patent/AR055953A1/es not_active Application Discontinuation
-
2007
- 2007-01-30 IL IL181070A patent/IL181070A0/en unknown
- 2007-02-02 NI NI200700031A patent/NI200700031A/es unknown
- 2007-02-07 CR CR8912A patent/CR8912A/es unknown
- 2007-02-16 EC EC2007007263A patent/ECSP077263A/es unknown
- 2007-02-16 MA MA29685A patent/MA28804B1/fr unknown
-
2009
- 2009-04-27 AU AU2009201650A patent/AU2009201650B2/en not_active Ceased
- 2009-04-27 AU AU2009201652A patent/AU2009201652B2/en not_active Ceased
-
2010
- 2010-01-13 US US12/686,843 patent/US8450372B2/en active Active
- 2010-01-13 US US12/686,830 patent/US20100113829A1/en not_active Abandoned
- 2010-01-13 US US12/686,812 patent/US8288440B2/en active Active
-
2011
- 2011-07-19 JP JP2011157930A patent/JP5308486B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502628A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| DOP2006000170A (es) | Nuevos derivados de espirocromanona | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| CL2010001260A1 (es) | Composicion farmaceutica que comprende una sal de estroncio y vitamina d y una ciclodextrina, donde la relacion masica entre la cantidad de vitamina d y la cantidad de ciclodextrina esta comprendida entre 1/40 y 1/800, util para tratar o prevenir osteoporosis. | |
| EA201171399A1 (ru) | Способ и композиция для улучшения всасывания лекарственных средств | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| BR112012020731A2 (pt) | pastilhas gelatinosas suaves com nicotina. | |
| NZ602510A (en) | Treatment of lupus nephritis using laquinimod | |
| DK2150530T3 (da) | Substituerede sulfonamid-derivater | |
| EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| CY1118032T1 (el) | Διεργασιες για την εμπορικη παρασκευη φαρμακευτικα δραστικου παραγοντα | |
| BR112012015433A2 (pt) | composição farmacêutica substancialmente anidra para aplicação cutânea | |
| EA201071043A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1 | |
| PL2244703T3 (pl) | Lekarstwo, jego wytwarzanie i zastosowanie w leczeniu bolesnych neuropatii | |
| CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. | |
| EA201400064A1 (ru) | Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб | |
| NI200700031A (es) | Formulaciones de ácido hidroxamico suberoilanilida y procedimientos para la producción de las mismas | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| MX2015010434A (es) | Derivados de acido bisfenil-butanoico sustituido como inhibidores de la endopeptidasa neutra (nep), con una mayor eficacia in vivo. | |
| EA201500366A1 (ru) | Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора | |
| AR113804A1 (es) | Formulaciones de un inhibidor de la quinasa trk macrocíclica | |
| CY1110563T1 (el) | Παραγωγο του ισοξαζολικου οξεος για την ανακουφιση νευροπαθητικου πονου | |
| UY32172A (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes de curacion de heridas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |